Cross-Sector entity
GoodRx is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. Coverage clusters in earnings, which accounts for 1 of those 4, with the remainder spread across 3 other categories. Each carries 9.5 original sources on average.
4 verified stories tracked
Last mentioned: Feb 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
GoodRx is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. Coverage clusters in earnings, which accounts for 1 of those 4, with the remainder spread across 3 other categories. Each carries 9.5 original sources on average. We currently track 4 Cross-Sector stories that mention Intellia Therapeutics, all published on February 26, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Intellia Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Functional Cure Declared
Medical reports confirm the patient is effectively cured of the rare disease.
Long-term Follow-up
B.C. patient reports zero attacks one year after single dose.
Phase 1/2 Results
Intellia releases early data showing significant reduction in HAE attacks.
Payoneer reported robust Q4 2025 results, driven by double-digit growth in B2B volume and strategic expansion into emerging markets. The broader mid-cap landscape shows a divergence between high-growth consumer brands like Celsius and R&D-heavy biotech firms navigating a complex regulatory environment.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
A British Columbia man has been declared functionally cured of Hereditary Angioedema (HAE) following a world-first in-vivo CRISPR gene-editing treatment. The success of Intellia Therapeutics' NTLA-2002 therapy marks a pivotal shift from chronic disease management to permanent genetic correction.
